A local coverage process may be better suited than a national coverage determination to effectively address advances in transcatheter aortic valve replacement (TAVR) technologies and indications, some stakeholders say.
In public comments submitted to CMS by Oct. 28, a range of device firms, health care providers, physicians and advocacy groups voiced a preference for local coverage following the Medicare...